E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cystic Fibrosis Lung infections |
Cystische Fibrose Luchtweginfecties |
|
E.1.1.1 | Medical condition in easily understood language |
Cystic Fibrosis Lung infections |
Cystische Fibrose / taaislijmziekte Luchtweginfecties |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the pharmacokinetic properties of dry powder tobramycin via the Cyclops® at different dosages in children with cystic fibrosis, together with the local tolerability. |
Onderzoek van de farmacokinetiek en de lokale verdraagzaamheid van droog poeder tobramycine bij kinderen met cystische fibrose. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Niet van toepassing |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Clinical diagnosis of CF and a positive sweat test or two CF-related mutations - Age 6 - 18 years - Ability to breathe through a mouthpiece and to use the Cyclops - Ability to perform pulmonary function tests - Written informed consent (child and parents) |
- Klinische diagnose van CF met een positieve zweettest of twee CFgerelateerde mutaties - Leeftijd 6-18 jaar - Vermogen om de Cyclops te gebruiken - Vermogen om spirometrie te blazen - Verkregen informed consent |
|
E.4 | Principal exclusion criteria |
- Acute exacerbation - FEV1 < 60% - Subjects with known or suspected renal, auditory, vestibular of neuromuscular dysfunction, or with severe, active haemoptysis - History of adverse events on previous tobramycin or other amino glycoside use - History of adverse events on the use of powder inhaler - Concurrent use of cyclosporine, amphotericin B, cephalosporins, polymyxins, vancomycin and NSAID's |
- Acute exacerbatie - FEV1 < 60% - Personen met bekende of vermeende nier-, gehoor of neuromusculaire disfunctie, of met ernstige en actieve hemoptysis - Voorgeschiedenis met bijwerkingen van eerder tobramycine gebruik of andere aminoglycoside - Voorgeschiedenis met bijwerkingen van eerder poederinhalatie - Gelijktijdig gebruik van ciclosporine, amphothericine B, cefalosporinen, polymyxinen, vancomycine en NSAID's |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The following pharmacokinetic parameters will be calculated: - AUC0 to 8-12 (area under the curve from 0 to 8-12 h) |
De volgende farmacokinetische parameters worden berekend: - AUC0 tot 8-12 (area under the curve from 0 tot 8-12 h) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Within four weeks after the last test dose |
Binnen vier weken na de laatste test dosering |
|
E.5.2 | Secondary end point(s) |
The following pharmacokinetic parameters will be calculated: - Actual dose (dose minus remainder in inhaler after inhalation) - Cmax (maximum plasma concentration) - Tmax (time to maximum plasma concentration) - Ka (absorption rate constant) - T 1/2 el (terminal elimination half-life) - CL/F (clearance following pulmonary administration (F= bioavailability))
Local tolerability of the inhalation of dry powder tobramycin. Both points need to have a positive result. - Drop of FEV1 of >10% (lung function measurement) - Adverse events |
De volgende farmacokinetische parameters worden berekend:- Actuele dosis (dosis minus het restant in de inhaler na inhalatie) - Cmax (maximum plasma concentration) - Tmax (time to maximum plasma concentration) - Ka (absorption rate constant) - T 1/2 el (terminal elimination half-life) - CL/F (clearance following pulmonary administration (F= bioavailability))
Lokale verdraagzaamheid van de inhalatie van droog poeder tobramycine. Beide punten moeten een positief resultaat hebben: - Daling van FEV1 of >10% (longfunctie meting) - Bijwerkingen |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Not applicable |
Niet van toepassing |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |